American researchers are making meaningful strides in refining the approach to GLP-1 receptor agonist therapy, moving beyond a one-size-fits-all model. These medications, initially developed for type 2 diabetes, have gained prominence for their weight loss benefits, but individual responses vary considerably. The goal is to identify biomarkers and patient characteristics that predict optimal responses to specific GLP-1 drugs.
GLP-1 Treatments: Personalized Medicine for American Patients - News Directory 3
By Dr. Jennifer Chen